Human medicines European public assessment report (EPAR): Retsevmo, selpercatinib, Carcinoma, Non-Small-Cell Lung;Thyroid Neoplasms, Date of authorisation: 11/02/2021, Revision: 8, Status: Authorised

Submitted by Anonymous (not verified) on 22 September 2023 - 11:00

Human medicines European public assessment report (EPAR): Retsevmo, selpercatinib, Carcinoma, Non-Small-Cell Lung;Thyroid Neoplasms, Date of authorisation: 11/02/2021, Revision: 8, Status: Authorised

Link: 
https://www.ema.europa.eu/en/medicines/human/EPAR/retsevmo
Source: 
What's new

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More